Trial Profile
Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Epistaxis; Hereditary haemorrhagic telangiectasia
- Focus Therapeutic Use
- Acronyms EROSB
- 02 Oct 2020 Planned End Date changed from 1 Jan 2017 to 1 Dec 2021.
- 02 Oct 2020 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2020.
- 26 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.